Enzon Pharmaceuticals (OTCMKTS:ENZN) and LogicBio Therapeutics (NASDAQ:LOGC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.


This table compares Enzon Pharmaceuticals and LogicBio Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Enzon Pharmaceuticals N/A 54.53% 46.94%
LogicBio Therapeutics N/A -52.99% -48.49%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Enzon Pharmaceuticals and LogicBio Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enzon Pharmaceuticals 0 0 0 0 N/A
LogicBio Therapeutics 0 0 3 0 3.00

LogicBio Therapeutics has a consensus target price of $23.00, indicating a potential upside of 148.65%. Given LogicBio Therapeutics’ higher probable upside, analysts clearly believe LogicBio Therapeutics is more favorable than Enzon Pharmaceuticals.

Institutional & Insider Ownership

0.1% of Enzon Pharmaceuticals shares are held by institutional investors. Comparatively, 56.5% of LogicBio Therapeutics shares are held by institutional investors. 0.1% of Enzon Pharmaceuticals shares are held by company insiders. Comparatively, 49.9% of LogicBio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Enzon Pharmaceuticals and LogicBio Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Enzon Pharmaceuticals $6.92 million 1.41 $5.85 million N/A N/A
LogicBio Therapeutics N/A N/A -$17.62 million ($3.04) -3.04

Enzon Pharmaceuticals has higher revenue and earnings than LogicBio Therapeutics.


Enzon Pharmaceuticals beats LogicBio Therapeutics on 5 of the 9 factors compared between the two stocks.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron for use in the treatment of chronic hepatitis C; and Sylatron for use in the treatment of melanoma disease. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Enzon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.